Table1 Characteristics of patients admitted to ICU with univariate comparisons.
Patients characteristics | Bloodstream infection patients (n = 71) n(%)/median (IQR) | Without bloodstream infection patients (n = 200) n (%)/median (IQR) | Univariate analysis | |
|---|---|---|---|---|
OR (95% CI) | p value | |||
Demographics | ||||
Male | 54 (76.06) | 136 (68.00) | 1.004 (0.555–1.817) | 0.990 |
Age | 74 (65–84) | 69.5 (56–78) | – | 0.072 |
Fever (≥ 38 °C) | 40 (56) | 123 (62) | 0.808 (0.467–1.398) | 0.445 |
Chronic comorbidity | ||||
COVID-19 | 12 (17) | 21 (11) | 1.734 (0.804–3.736) | 0.156 |
Gastrointestinal | 43 (61) | 95 (48) | 1.697 (0.978–2.945) | 0.059 |
Respiratory | 44 (62) | 105 (53) | 1.474 (0.848–2.565) | 0.168 |
Cardiovascular | 31 (44) | 81 (41) | 1.139 (0.659–1.968) | 0.642 |
Renal | 28 (39) | 83 (42) | 0.918 (0.528–1.596) | 0.761 |
Neurologic | 23 (32) | 101 (51) | 0.470 (0.266–0.830) | 0.009* |
Metabolic disorders | 45 (63) | 118 (59) | 1.203 (0.688–2.104) | 0.517 |
Immunocompromise | 12 (16.9) | 43 (21.5) | 0.743 (0.366–1.505) | 0.408 |
Severity at BSI onset | ||||
Shock | 46 (65) | 83 (42) | 2.594 (1.478–4.552) | 0.001* |
APACHE II score > 15 | 47 (66.2) | 130 (65) | 1.054 (0.596–1.867) | 0.856 |
Treatment interventions before infections events | ||||
Surgical intervention | 33 (46) | 75 (38) | 1.436 (0.830–2.482) | 0.194 |
Enteral feeding | 44 (62) | 151 (76) | 0.529 (0.297–9.942) | 0.029* |
Trauma | 6 (8) | 20 (10) | 0.831 (0.320–2.160) | 0.703 |
Gastrointestinal bleeding | 15 (21) | 19 (10) | 2.552 (1.217–5.350) | 0.011* |
Transfusion | 39 (55) | 88 (44) | 1.551 (0.900–2.674) | 0.113 |
Dialysis therapy | 29 (41) | 54 (27) | 1.867 (1.059–3.291) | 0.03* |
Tracheotomy | 25 (35.2) | 31 (15.5) | 2.963 (1.595–5.505) | < 0.001* |
Ventilator | 47 (66.2) | 145 (72.5) | 0.743 (0.415–1.329) | 0.315 |
Central venous catheter | 53 (74.6) | 132 (66) | 1.517 (0.825–2.790) | 0.179 |
Outcome | ||||
Length of stay | ||||
Total hospital stay (d) | 30 (13–53) | 21 (11–35) | – | < 0.001* |
ICU stay (d) | 21 (8–41) | 15 (8–26) | – | < 0.001* |
Mortality | 25 (35.21) | 40 (20) | 2.174 (1.196–3.952) | 0.01* |
Laboratory parameter | ||||
Alkaline phosphatasea | 102.5 (75.75–173.5) | 81 (58–113) | – | 0.005* |
Alanine transaminasea | 34 (15–85) | 27 (13–55.75) | – | 0.951 |
Aspartate aminotransferasea | 44 (26–89) | 39 (20–80) | – | 0.64 |
γ-glutamyl transpeptadasea | 61 (40–121) | 33 (20–87.5) | – | 0.013* |
Total bilirubin levelb | 22.9 (15.2–56) | 17.3 (10.93–30.45) | – | 0.095 |
Direct bilirubinb | 8.2 (4.3–31.9) | 5.3 (2.93–11.48) | – | 0.099 |
Total biliary acidb | 5.55 (3.18–16.58) | 4.1 (2.3–8.5) | – | 0.263 |
Cholyglycineb | 3.1 (1.8–9.9) | 2 (1.5–3.9) | – | 0.067 |
Total proteinc | 59.5 (51.5–66.25) | 58 (52.25–63) | – | 0.298 |
Serum creatinine levelb | 105 (71–154) | 92 (66–158.75) | – | 0.975 |
Brain natriuretic peptided | 698 (237.75–1599.25) | 273 (104.5–856.5) | – | 0.02* |
Procalcitonine | 6.34 (1.23–52) | 0.69 (0.24–3.85) | – | < 0.001* |
Hematocrit | 0.27 (0.21–0.34) | 0.3 (0.25–0.34) | – | 0.022* |
Hemoglobinc | 87 (70–113) | 98 (82–115.75) | – | 0.008* |
Leukocyte countf | 9.3 (6.54–18.12) | 11 (7.41–14.29) | – | 0.788 |
Neutrophil countf | 8.16 (5.62–17.21) | 9.41 (6.18–12.41) | – | 0.328 |
Lymphocyte countf | 0.58 (0.33–0.98) | 0.69 (0.45–1.04) | – | 0.547 |
Monocyte countf | 0.3 (0.17–0.62) | 0.48 (0.28–0.76) | – | 0.08 |
Mean platelet volume (fl) | 10.8 (9.88–12.13) | 10.3 (9.4–11.3) | – | 0.003* |
Platelet countf | 113 (44–203) | 151 (102–220) | – | 0.023* |
Erythrocyte countf | 2.91 (2.23–3.66) | 3.24 (2.68–3.89) | – | 0.017* |
CRP (mg/L) | 143.5 (93–200) | 96.5 (40.25–164.75) | – | < 0.001* |
Antibiotic usage | ||||
Antifungal agents | 30 (42) | 123 (62) | 0.458 (0.264–0.794) | 0.005* |
Fluoroquinolone | 24 (34) | 71 (36) | 0.928 (0.524–1.642) | 0.797 |
Peptide antibiotic | 30 (42) | 110 (55) | 0.599 (0.346–1.035) | 0.065 |
Cephalosporin | 35 (49) | 153 (77) | 0.299 (0.169–0.527) | < 0.001* |
Carbapenem | 52 (73) | 152 (76) | 0.864 (0.466–1.603) | 0.643 |
Tigecycline | 13 (18) | 14 (7) | 2.978 (1.324–6.697) | 0.006* |
Linezolid | 21 (30) | 75 (38) | 0.700 (0.390–1.256) | 0.231 |